Cambridge, MA | August 2026 A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats - ScienceDire
Cambridge, MA | August 2026 Clear Scientific, a clinical-stage biopharmaceutical company, was awarded a $5.2M award from the NIH’s National Institute on Drug Abuse to continue the development of CS-1
Portland, OR | June 2026 Piercen Oliver PhD, VP of R&D and Xinhua Li PhD, Executive Vice President Drug Development of Clear Scientific Inc. presented at the 88th Annual Scientific Meeting of the Col
Comments